glp 1 drugs cost comparison for GLP-1 agonist Self Pay Novo's GLP-1s Highlight List as

After informed discussion of risks, benefits, and cost, patient preference is a valid reason

Clinical Observations and Evidence Recent clinical data published in the New England Journal of Medicine demonstrated that standard-dose semaglutide administration resulted in an average 15% reduction in body weight over 68 weeks

In a cohort of 3731 patients, weight loss of 5%, 10%, and 15% was observed in 63%, 33%, and 14%, respectively, after 56 weeks of treatment (27%, 11%, and 4% with placebo),69 or of an additional 6% at 56 weeks in patients who had already lost 6% through hypocaloric diet and exercise.70 Positive results were also observed in adolescent patients with obesity,71 and in real-life studies substantial weight loss has also been reported.7275 Phase 3 trials with GLP-1 receptor agonists indicated specifically for obesity and overweight

A meta-analysis shows that 35% of patients reached a 75% improvement in PASI scores following 6 to 12 weeks of GLP-1RA therapy, but many patients show minimal improvement demonstrating response variability [66]

But its not a simple problem of low GLP-1 = bad

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes